OECDReferencia EN/AU/PS1090417
Dexcom G4 Platinum, G5 Mobile and G6 Sensor Glucose Monitoring System
Información oficial organizada para facilitar su consulta. La publicación de la fuente conserva la autoridad.
Identificación
Identificación del producto
- Producto
- Dexcom G4 Platinum, G5 Mobile and G6 Sensor Glucose Monitoring System
Información oficial
Riesgo y medidas
- Riesgo o peligro
- The Dexcom Continuous Glucose Monitoring System may show falsely elevated glucose readings for users who are taking hydroxyurea, an anti-neoplastic drug, used primarily in chemotherapy. Incorrect glucose readings may result in incorrect diabetes treatment decisions. If incorrect information is used to make treatment decisions, this could lead to an incorrect dose of insulin. This may result in failure to treat low blood glucose (hypoglycemia, loss of consciousness, seizure, death) from missed low sensor glucose values and alerts or by causing other errors (for example, hypoglycemia from an insulin dose based on a falsely elevated sensor glucose reading) and may lead to serious health complications.
- Recomendaciones
- AA-Med Pty Ltd will contact affected users in writing. When using the G4 Platinum, G5 Mobile or G6 Sensor, consumers should read the additional information in the warning sections of the Instructions For Use (IFU) relating to hydroxyurea. The updated warning is as follows: If you are taking hydroxyurea, your glucose readings may be falsely elevated and result in missed hypoglycemia alerts or errors in diabetes management. The level of inaccuracy depends on the amount of hydroxyurea in your body. Use your meter. For further information, contact Australasian Medical & Scientific Customer Service by phone on 1300 851 056.
Información oficial
Operadores económicos
- Fabricante
- AA-Med Pty Ltd
Territorio
Geografía
- Distribución
- Retirada en Australia
- País de retirada
- Australia
Procedencia y contexto
NagameAlert distingue el contenido publicado por la fuente de su organización y normalización. Los valores marcados como «NagameAlert» pertenecen a esa capa de tratamiento. Comprueba siempre medidas, alcance y actualizaciones en la publicación oficial.